Micreos Raises EUR30 Million for Endolysin Technology Set to Replace Antibiotics / Funding for clinical development program XZ.700 and Gladskin Eczema USA launch

THE HAGUE, Netherlands (ots) - Dutch biotechnology company Micreos
announced it has secured EUR30 million in funding to accelerate the
development of its endolysin technology, set to replace antibiotics.
Proceeds are earmarked for the clinical development program of its
endolysin XZ.700 and the USA launch of its breakthrough OTC Gladskin
product for eczema.

According to the World Health Organization, antibiotic resistance
is one of the world's biggest health threats. The call for true
alternatives is more pressing than ever. Antibiotics do not
distinguish between bad and good bacteria, and their use induces
resistance.

Endolysins have three distinct features: (1) ability to target
only unwanted bacteria while preserving the microbiome, which is
essential for our health. (2) ability to kill antibiotic resistant
strains of bacteria (3) emergence of resistance against endolysins is
not expected.

Endolysin technology opens a new therapeutic window for treatment
of chronic inflammatory conditions, such as atopic dermatitis and
persistent wound infections, including those caused by MRSA.

Micreos' Staphefekt(TM) SA.100, is the world's first endolysin
approved for human use. It selectively targets Staphylococcus aureus
- often referred to as 'Staph' - which is a major trigger of eczema
and other inflammatory skin conditions.

Video: How Staphefekt(TM) works in eczema:
https://youtu.be/qxg2kxfFw6Q

"Since its introduction, Gladskin has helped over 100.000 people
in Europe with eczema, acne, and rosacea, many of them reporting a
life-changing impact,'' remarked Skyler Stein, Head of Gladskin USA.
"Gladskin is pioneering the use of endolysins to rebalance the skin
microbiome and improve skin health." Chosen as Europe's Most
Impactful Innovation 2018, Gladskin is now preparing its launch in
the United States.

The EUR30 million funding includes a non-dilutive EUR5.4 million
Innovation Credit granted by the Dutch Ministry of Economic Affairs.
Micreos has conducted several studies with Gladskin, including trials
on eczema, acne and rosacea. Studies in orphan indications with a
high unmet need, like primary immune deficiencies and Netherton
disease are ongoing.

Micreos CEO Mark Offerhaus noted: "This funding from existing and
new investors will advance the adoption of our endolysin technology
and help us reach the millions who stand to benefit. We are exploring
partnerships to further accelerate the commercialization of our
technology."

About Micreos

Micreos is a Dutch biotechnology company with production and R&D
centers for endolysins in Bilthoven and for phages in Wageningen.
Micreos maintains a long-term collaboration with ETH Zurich (Prof
Loessner) in Switzerland and numerous medical and technology centres,
including Erasmus MC (Rotterdam), the Public Health Lab Kennemerland,
the Dutch Burn Centres (Beverwijk), Copenhagen University and many
others. Gladskin is a Micreos Human Health brand (www.gladskin.com)
for inflammatory skin conditions such as eczema, inflammatory acne,
psoriasis and rosacea. Phageguard is the Micreos Food Safety brand
for FDA- and USDA-approved phage products against Listeria,
Salmonella and E. coli (www.phageguard.com).

Websites: www.micreos.com, www.gladskin.com, www.phageguard.com

Photos:
https://mma.prnewswire.com/media/843302/Skyler_Headshot.jpg
https://mma.prnewswire.com/media/843301/Micreos_IdeasFromEurope.jpg
https://mma.prnewswire.com/media/843300/Gladskin_products_30_ml.jpg

Contact:
For further information:
info@micreos.com, Dirk de Meester: +31-6-46048503,
d.demeester@micreos.com

Original-Content von: Micreos, übermittelt durch news aktuell